A new series of blood group A and H antigens expressed in human erythrocytes and the incompatible A antigens expressed in tumours of blood group 0 and B individuals
Results of previous studies from our laboratories on the isolation and characterization of erythrocyte glycolipids with blood group A and B activities can be summarized as follows:
( I ) Four A-active and four H-active glycosphingolipid components, termed A", Ah, A , Ad, and H I , H,, H, and H,, have been isolated and their structures have been elucidated, as shown in Table 1 . H I , H,, A", and Ah represent unbranched Type 2 chain carrying H and A determinants, respectively, whereas H,, H,, A' , and Ad contain branched Type 2 chains as the carrier (Hakomori et al., 1972 (Hakomori et al., , 1979 Watanabe et al., 1975) .
(2) The unbranched molecular species ( H I , H,, A", Ab) predominate in fetal and newborn erythrocytes, while the branched molecular species (H3, H,, A and Ad) predominate in adult erythrocytes. Thus the development from newborn to adult erythrocytes is associated with unbranched to branched Type 2 chain (Watanabe & Hakomori, 1976 ; for a review of other data see Hakomori, 1981) .
(3) These Type 2 chain A and H antigens and their unsubstituted core structures which express the i and I antigens are also carried by intrinsic proteins of human erythrocytes, which are known as Band 3 and Band 4.5 glycoproteins (Fukuda et al., 1979) .
These Type 2 chain blood group antigens constitute the major components of human erythrocytes, and their chemistry and developmental patterns have been reviewed previously (Hakomori, 1981) .
New series qf'bloodgroup A and H glycosphingolipid antigens in human erythrocytes
In addition to the major branched and unbranched Type 2 chain antigens described above, new series of ABH active glycolipid antigens have been clearly identified in recent years with the introduction of monoclonal antibodies that recognize specific A and H determinants with specific combinations of carrier carbohydrate chains. Importantly, these antibodies recognize not only A and H determinants, but also internal regions of the carbohydrate chains as well, although the exact epitopes defined by these antibodies are not known.
Type 1 chain A (ALed and A h ' ) . The monoclonal antibody AH21 was produced by immunization with a purified monofucosyl Type 1 chain A (ALed) isolated from human gastric cancer cell line MKN45. The antibody does not react with difucosyl Type 1 chain A (ALe') shown in Table 2 or any other type of A determinant tested (Abe et al., 1984) . A single ALed glycolipid recognized by this antibody was detected only in erythrocytes of Le(a-b-c-d + ) , i.e. erythrocytes from rare individuals who are Le(a -b -) secretors. The ALed antigen was isolated and characterized by n.m.r. and methylation analysis (Clausen et al., 1985~) . Another monoclonal antibody, HH3, specifically reacts with difucosyl Type I chain A (ALe') and does not react with monofucosyl Type 1 chain A or any other A determinant tested (Clausen et al., 19856) . The antigen defined by this antibody was detected in relatively large Vol. 15 quantities in Le(a-b + c-d-) individuals, i.e. the majority of the secretor population carries this antigen, although the quantity is far less than Type 2 chain A or Type 3 chain determinants (Clausen et al., 19856) .
Type 3 chain A ( A , antigen) and Type 3 chain H (A-associated H or A , antigen). Type 3 chain A was incidentally discovered during studies with the monoclonal antibody TH I , which was originally prepared by immunization with what was presumed to be purified A' antigen. This preparation was subsequently shown to contain Type 3 chain A as the major component. The original intention was to obtain a monoclonal antibody that could distinguish branched Type 2 chain A (A') from unbranched A (Ah, A"). TH 1 specifically reacts with a series of glycosphingolipids, some of which co-migrate on t.1.c. with glycolipids previously designated Ab, A and Ad. These new components were isolated after acetylation and purification on preparative high-performance t.1.c. The structures were determined by n.m.r. and methylation analysis as shown in Table 3 . Interestingly, these structures represent repetitive A, i.e. an extension of hitherto known A determinants. Up to now, two molecular species (n = 1 or 2), as shown in Table 3 , have been characterized (Clausen et a / . , 1985c, 1 9 8 6~) . These structures were detected in A , erythrocytes, but not in A, erythrocytes, and can be regarded as the classical A, antigen. The precursor of Type 3 chain A, i.e. Type 3 chain H, was detected in A, erythrocytes and in much smaller amounts in A, erythrocytes. This antigen was recently isolated and characterized (Clausen et al., 1 9 8 6~) .
The structure of Type 3 chain H shown in Table 3 was determined by n.m.r. spectroscopy and methylation analysis. Type 3 chain H reacts with monoclonal antibody MBrl, which was previously shown to be directed to globo-H structure (type 4 chain H structure; Table 4) (Bremer et al., 1984) . The antigen determined by the MBrl antibody was found to be strongly expressed in human teratocarcinoma cells (Kannagi et al., 1983) and human breast cancer cells (Bremer et al., 1984) . Since the MBrl-defined antigen was found in greater quantity in A, erythrocytes than in A, erythrocytes and MBrl specifically agglutinates A, but not A, erythrocytes after sialidase treatment, the MBrl-defined antigen can be regarded as the classical A, antigen (H. Clausen & S. Hakomori, unpublished work) .
Type 4 chain A (globo-A) and H (globo-H) antigens. Previously a glycolipid designated as A" antigen was detected only in A, erythrocytes but not in A, erythrocytes. A" had hi h-performance t.1.c. migration in between that of Aa and A (Watanabe et al., 1980) . The antigen was later isolated from erythrocytes and characterized by n.m.r. and methylation analysis as globo-A (Clausen et al., 1984 ) (see Table 4 ). The precursor for globo-A, the globo-H antigen, was previously isolated from the human teratocarcinoma cell line 2102 (Kannagi et al., 1983) and from breast carcinoma (Bremer et d., 1984) , but the quantity of this antigen in 0 erythrocytes was extremely small. It was finally isolated and characterized after repeated chromatography as an acetate . The globo-A and globo-H antigens are hereby termed Type 4 chain A and Type 4 chain H, and their structures are shown in Table 4 .
Expression of incompatible A antigen in tumours of blood group 0 and B individuals
Although the presence of an A-like or A-cross-reacting antigen in tumours of blood group 0 or B individuals has been known for a long time, the chemical nature of the epitopes have only recently been determined. Since we have a 
Classical Ad (now A')
/" established many monoclonal antibodies directed at specific A determinants or A-related structures, this topic has been studied more systematically than previously. Monoclonal antibodies originally raised to squamous cell carcinomas of the lung and reacting with a large variety of human cancers, were found to bind to blood group A antigen, and the epitope was eventually identified as GalNAccr -+ 0-Ser/or Thr. This structure has been known as Tn antigen as identified by Springer et al. (1974) . One of the antibodies, NCC-LU-35, cross-reacts more strongly with A antigen than the other antibody, NCC-LU-81. There is evidence which clearly indicates that the majority of the A-like antigen expressed in non-A tumours is in fact Tn antigen (Hirohasi e t al., 1985) . By appropriate selection an anti-Tn antibody may be prepared which does not cross-react with A antigen at all, and such an antibody may indeed be useful for diagnosis and treatment of human cancer (H. Takahashi, & S. Hakomori, unpublished work) . On the other hand, about 10-15% of non-A colonic cancer express Type 1 chain A antigen, either mono-or di-fucosyl, defined by monoclonal antibody AH21 or HH3 (Clausen et al., 1986d) . Since these epitopes are expressed in tumours from non-A persons, we raise the possibility that, the A transferase gene may not be a specific product of A individuals, but may rather be suppressed in normal B or 0 tissues.
